widespread potential growth-factor-driven resistance anticancer kinase inhibitors 
mutationally activated kinases define clinically validated class targets cancer drug therapy1 however efficacy kinase inhibitors patients whose tumours harbour alleles invariably limited innate acquired drug resistance23 identification resistance mechanisms revealed recurrent theme-the engagement survival signals redundant transduced targeted kinase4 cancer cells typically express multiple receptor tyrosine kinases rtks mediate signals converge common critical downstream cell-survival effectors-most notably phosphatidylinositol--oh kinase pi3k mitogen-activated protein kinase mapk5 consequently increase rtk-ligand levels autocrine tumour-cell production paracrine contribution tumour stroma6 systemic production confer resistance inhibitors oncogenic kinase similar signalling output using panel kinase-addicted human cancer cell lines found cells can rescued drug sensitivity simply exposing one rtk ligands among findings clinical implications observation hepatocyte growth factorhgf confers resistance braf inhibitor plx4032 vemurafenib braf-mutant melanoma cells observations highlight extensive redundancy rtk-transduced signalling cancer cells potentially broad role widely expressed rtk ligands innate acquired resistance drugs targeting oncogenic kinases 
